1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Molecular Insight Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Molecular Insight Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Molecular Insight Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Molecular Insight Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Molecular Insight Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Molecular Insight Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Molecular Insight Pharmaceuticals, Inc. - Brief Molecular Insight Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Molecular Insight Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Molecular Insight Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Molecular Insight Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Molecular Insight Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Molecular Insight Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Molecular Insight Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Molecular Insight Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Molecular Insight Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Molecular Insight Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Molecular Insight Pharmaceuticals, Inc. Snapshot 5
Molecular Insight Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Molecular Insight Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Molecular Insight Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Molecular Insight Pharmaceuticals, Inc. - Pipeline Products Glance 10
Molecular Insight Pharmaceuticals, Inc. - Late Stage Pipeline 10
Phase III Products/Combination Treatment Modalities 10
Molecular Insight Pharmaceuticals, Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Molecular Insight Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Molecular Insight Pharmaceuticals, Inc. - Drug Profiles 13
[I131] MIP-1095 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
edotreotide labeled yttrium 90 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
iobenguane I 131 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
MIP-1375 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
MIP-1407 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Molecular Insight Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 20
Molecular Insight Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 21
Molecular Insight Pharmaceuticals, Inc. - Recent Pipeline Updates 22
Molecular Insight Pharmaceuticals, Inc. - Dormant Projects 24
Molecular Insight Pharmaceuticals, Inc. - Locations And Subsidiaries 25
Head Office 25
Molecular Insight Pharmaceuticals, Inc., Recent Developments 26
Molecular Insight Pharmaceuticals, Inc.- Press Release 26
Jun 23, 2010: Molecular Insight Presents Positive Data From Azedra Phase IIa Trial In Neuroblastoma 26
Apr 12, 2010: Molecular Insight's Onalta Phase II Data Published In Journal Of Clinical Oncology 27
Mar 22, 2010: Molecular Insight Advances Solazed For Malignant Melanoma Into Phase I Clinical Trial 28
Financial Deals Landscape 30
Molecular Insight Pharmaceuticals, Inc., Deals Summary 30
Molecular Insight Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deal Details 31
Asset Transactions 31
Molecular Insight Acquires RadioPharma Manufacturing Facility From NeoRx Manufacturing 31
Molecular Insight Pharma Acquires Manufacturing Facility From NeoRx Manufacturing 33
Licensing Agreements 35
Molecular Insight Pharma Enters Into A Licensing Agreement With Biomedica Life Sciences 35
Molecular Insight Enters Into Licensing Agreement With Novartis Pharma 37
Molecular Insight Enters Into An Licensing Agreement With Bayer Schering Pharma 39
Equity Offering 40
Molecular Insight Announces Private Placement Of $45 Million With Savitr Capital 40
Molecular Insight Pharma Files Shelf Registration Statement For $250 Million 42
Molecular Insight Pharma Completes IPO Of $70 Million 44
Debt Offering 46
Molecular Insight Completes Private Placement Of Floating Rate Bonds For $150 Million 46
Acquisition 47
Progenics Pharma Acquires Molecular Insight Pharma For Up To $106 Million 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50



List of Tables

Molecular Insight Pharmaceuticals, Inc., Key Information 5
Molecular Insight Pharmaceuticals, Inc., Key Facts 5
Molecular Insight Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Molecular Insight Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Molecular Insight Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Molecular Insight Pharmaceuticals, Inc. - Phase III, 2013 10
Molecular Insight Pharmaceuticals, Inc. - Phase II, 2013 11
Molecular Insight Pharmaceuticals, Inc. - Pre-Clinical, 2013 12
Molecular Insight Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 20
Molecular Insight Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 21
Molecular Insight Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 22
Molecular Insight Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 24
Molecular Insight Pharmaceuticals, Inc., Deals Summary 30
Molecular Insight Acquires RadioPharma Manufacturing Facility From NeoRx Manufacturing 31
Molecular Insight Pharma Acquires Manufacturing Facility From NeoRx Manufacturing 33
Molecular Insight Pharma Enters Into A Licensing Agreement With Biomedica Life Sciences 35
Molecular Insight Enters Into Licensing Agreement With Novartis Pharma 37
Molecular Insight Enters Into An Licensing Agreement With Bayer Schering Pharma 39
Molecular Insight Announces Private Placement Of $45 Million With Savitr Capital 40
Molecular Insight Pharma Files Shelf Registration Statement For $250 Million 42
Molecular Insight Pharma Completes IPO Of $70 Million 44
Molecular Insight Completes Private Placement Of Floating Rate Bonds For $150 Million 46
Progenics Pharma Acquires Molecular Insight Pharma For Up To $106 Million 47



List of Figures

Molecular Insight Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
Molecular Insight Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
Molecular Insight Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
Molecular Insight Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 20
Molecular Insight Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.